CONCENTRATIONS OF TROVAFLOXACIN IN BRONCHIAL-MUCOSA, EPITHELIAL LINING FLUID, ALVEOLAR MACROPHAGES AND SERUM AFTER ADMINISTRATION OF SINGLEOR MULTIPLE ORAL DOSES TO PATIENTS UNDERGOING FIBEROPTIC BRONCHOSCOPY

Concentrations of trovafloxacin were measured in serum, alveolar macro phages, epithelial lining fluid and bronchial mucosa following single and multiple oral doses. Concentrations were determined using a microb iological assay method. There were 18 subjects in the single dose and nine subjects in the multiple dose groups. After single dosing, mean c oncentrations in serum, alveolar macrophages, epithelial lining fluid and bronchial mucosa at 6, 12 and 24 h were as follows: 6 h, 1.41 mg/L , 19.06 mg/L, 3.01 mg/L and 1.52 mg/kg; 12 h, 0.85 mg/L, 16.22 mg/L, 4 .8 mg/L and 1.01 mg/kg; 24 h, 0.37 mg/L, 10.23 mg/L, 0.93 mg/L, and no measurable concentration, respectively. After multiple dosing (approx imately 6 h post-dose) the corresponding concentrations were 1.47 mg/L , 34.3 mg/L, 10.21 mg/L and 1.67 mg/kg, respectively. These concentrat ions exceed the MICS90 for the common respiratory pathogens, Haemophil us influenzae 0.06 mg/L, Moraxella catarrhalis 0.008 mg/L and Streptoc occus pneumoniae 0.12 mg/L and suggest that trovafloxacin should be ef ficacious in the treatment of community- and hospital-acquired respira tory infections.